Skip to main content
PFEPfizer, Inc.Hold5.4·$28.44-1.28%

Pfizer (PFE) Q2 2026 earnings — TrendMatrix coverage

BEAT+12.9% vs estimateEPS $0.77 vs $0.68 estVerdict HoldBuy (Wait)

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.77
Estimate
$0.68
Surprise
+12.9%
Revenue (period 2026-06-28)
$15.03B
Score at report (before → after)
5.65.5/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Pfizer (PFE) beat the $0.68 estimate with diluted EPS of $0.77 — a large 12.9% upside surprise. TrendMatrix's engine moved from Hold (5.6/10) to Buy (Wait) at 5.5/10 after the report — the engine's score fell despite the beat.

Current read · as of 2026-09-05

Where TrendMatrix's rating stands now

TrendMatrix currently rates PFE Hold at 5.4/10.

4 of the last 4 quarters beat the estimate; this quarter's +12.9% surprise compares with a +17.6% four-quarter average. Next scheduled report: 2026-11-03.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Concentration risk — Product: top-12 products (65.0%)
  • Analyst target reached - limited upside remaining
  • Near 52-week high (2.6% away)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$28.44
Price target
$32.72
Stop
$27.21
Upside to target
+15.0%

The stock trades at 37.4× trailing but 9.8× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare context

PFE at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - General
Market cap
$162.16B
P/E (fwd)
9.8
P/E (ttm)
37.4
52-week range
$23.58$29.21
Off 52-week high
2.6%
RSI (14)
66
Volume vs avg
0.68×
Score today
5.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks PFE Earnings Q2 2026 earnings